Apo-A1

Apo-A1 Molekülinformation

Englischer Name	Apolipoprotein A-I	Anzahl der inverkehr gebrachten Arzneimittel	0
Anzahl der klinischen Arzneimittel	3	Target-Alias	Epididymis Secretory Sperm Binding Protein，Apolipoprotein A-I(1-242)，APOA1，ProapoA-I，Apo-AI，Apolipoprotein A1，Apo(A)，ApoA-I，Apolipoprotein A-I，HPALP2
Höchste Forschungs- und Entwicklungsphase	Phase 2 Clinical

Englischer Name	Apolipoprotein A-I
Target-Alias	Epididymis Secretory Sperm Binding Protein，Apolipoprotein A-I(1-242)，APOA1，ProapoA-I，Apo-AI，Apolipoprotein A1，Apo(A)，ApoA-I，Apolipoprotein A-I，HPALP2
Anzahl der inverkehr gebrachten Arzneimittel	0
Anzahl der klinischen Arzneimittel	3
Höchste Forschungs- und Entwicklungsphase	Phase 2 Clinical

Apo-A1 Produktliste

Attribut
Protein (1)
Produktbibliothek
Online (1)
Spezies
Human (1)
Etikett
His Tag (1)
Marker
Unconjugated (1)

Produktnummer	Spezies	Expressionssystem	Produktbeschreibung	Proteinstruktur	Reinheit	Eigenschaften	Vorbestellen/Bestellen
AP1-H5225	Human	HEK293	Human Apo-A1 Protein, His Tag				In den Warenkorb legen

Gesamtmenge1

Apo-A1 Molekülhintergrund

ApoA1 is also known as apolipoprotein A-I, ApoA-I , and is the major protein component of high density lipoprotein (HDL) in plasma. It has a specific role in lipid metabolism. Chylomicrons secreted from the intestinal enterocyte also contain ApoA1 but it is quickly transferred to HDL in the bloodstream. The protein promotes cholesterol efflux from tissues to the liver for excretion. It is a cofactor for lecithin cholesterol acyltransferase (LCAT) which is responsible for the formation of most plasma cholesteryl esters. ApoA-I was also isolated as a prostacyclin (PGI2) stabilizing factor, and thus may have an anticlotting effect. Defects in the gene encoding it are associated with HDL deficiencies, including Tangier disease, and with systemic non-neuropathic amyloidosis. In addition, it has been shown that ApoA1 is implicated in the anti-endotoxin function of HDL via interaction with lipopolysaccharide or endotoxin.

Apo-A1 Molekülalias

Apolipoprotein A-I,APOA1,MGC117399

Klinische Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Indikationen	Klinische Studie
Zerlasiran	SLN-360	Phase 2 Clinical	Silence Therapeutics Plc	Atherosclerosis; Cardiovascular Diseases; Dyslipidemias; Hyperlipidemias; Lipid Metabolism Disorders	Details
Fx-5A	Fx-5A	Phase 1 Clinical	Kinemed Inc	Cardiovascular Diseases	Details
Recombinant NV-A01 adenovirus		Phase 1 Clinical	Nanjing Nuowei Biotechnology Co Ltd	Glioblastoma; Solid tumours	Details